PMID- 30013320
OWN - NLM
STAT- MEDLINE
DCOM- 20190116
LR  - 20230926
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 12
DP  - 2018
TI  - Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a 
      meta-analysis and systematic review.
PG  - 2005-2016
LID - 10.2147/DDDT.S160431 [doi]
AB  - OBJECTIVE: To summarize updated evidences on the efficacy and safety of 
      adalimumab (ADA) in the treatment of patients with non-infectious uveitis. 
      PATIENTS AND METHODS: A systematic search between January 2000 and September 2017 
      was conducted using PubMed, Embase, and Cochrane libraries. We investigated 
      control of inflammation, improvement of visual acuity (VA), 
      corticosteroid-sparing effect, and adverse events (AEs) or serious adverse 
      events. RESULTS: Three randomized clinical trials (RCTs) and 20 non-RCTs were 
      included and analyzed. The pooled proportions of inflammation control were 74% 
      (95% CI 64%-82%) and 79% (95% CI 69%-87%) in groups of </=6- and >/=12-months 
      follow-up durations. No significant difference was found between the two groups 
      (chi(2) = 0.920, p = 0.337). Analysis of subgroups classified by degree of being 
      treatment-naive for anti-TNFalpha agents showed the inflammation control reached a 
      high of 87% (95% CI 80%-92%) when subjects were "almost naive" to anti-TNFalpha 
      before ADA treatment. VA was improved by three or more lines in 41.3% (52/126) 
      eyes, and was equal to or better than the baseline in 88.8% (142/160) eyes. 
      Corticosteroid sparing was observed in 82.0% (91/111) of the patients; among 
      them, 48.8% (40/82) discontinued use of corticosteroid completely. Minor 
      drug-related adverse events were reported. The treatment effects of ADA were 
      generally consistent in the three RCTs, and ADA reduced the risk of treatment 
      failure by 43%-75%. CONCLUSION: The current review provided evidences that ADA 
      might be a promising choice in reducing inflammatory activity, gaining VA, and 
      sparing corticosteroid use with minor AEs when applied in treating non-infectious 
      uveitis.
FAU - Ming, Shuai
AU  - Ming S
AD  - Clinical Research Center, Henan Eye Institute, Henan Eye Hospital, 
      bolei99@126.com.
AD  - Department of Ophthalmology, Henan Provincial People's Hospital, bolei99@126.com.
FAU - Xie, Kunpeng
AU  - Xie K
AD  - Clinical Research Center, Henan Eye Institute, Henan Eye Hospital, 
      bolei99@126.com.
AD  - Department of Ophthalmology, Henan Provincial People's Hospital, bolei99@126.com.
FAU - He, Huijuan
AU  - He H
AD  - Clinical Research Center, Henan Eye Institute, Henan Eye Hospital, 
      bolei99@126.com.
AD  - Department of Ophthalmology, Henan Provincial People's Hospital, bolei99@126.com.
FAU - Li, Ya
AU  - Li Y
AD  - Clinical Research Center, Henan Eye Institute, Henan Eye Hospital, 
      bolei99@126.com.
AD  - Department of Ophthalmology, Henan Provincial People's Hospital, bolei99@126.com.
FAU - Lei, Bo
AU  - Lei B
AD  - Clinical Research Center, Henan Eye Institute, Henan Eye Hospital, 
      bolei99@126.com.
AD  - Department of Ophthalmology, Henan Provincial People's Hospital, bolei99@126.com.
AD  - Department of Ophthalmology, People's Hospital of Zhengzhou University, 
      Zhengzhou, China, bolei99@126.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20180704
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (TNF protein, human)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab/*adverse effects/*therapeutic use
MH  - Humans
MH  - Inflammation/*drug therapy/metabolism
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors/metabolism
MH  - Uveitis/*drug therapy/metabolism
PMC - PMC6037408
OTO - NOTNLM
OT  - adalimumab
OT  - anti-TNF alpha
OT  - non-infectious uveitis
OT  - uveitis treatment
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/07/18 06:00
MHDA- 2019/01/17 06:00
PMCR- 2018/07/04
CRDT- 2018/07/18 06:00
PHST- 2018/07/18 06:00 [entrez]
PHST- 2018/07/18 06:00 [pubmed]
PHST- 2019/01/17 06:00 [medline]
PHST- 2018/07/04 00:00 [pmc-release]
AID - dddt-12-2005 [pii]
AID - 10.2147/DDDT.S160431 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2018 Jul 4;12:2005-2016. doi: 10.2147/DDDT.S160431. 
      eCollection 2018.